Ensysce Biosciences, Inc. (ENSC) Revenue History
Annual and quarterly revenue from 2017 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ENSC Revenue Growth
Revenue Breakdown (FY 2023)
ENSC's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
ENSC Revenue Analysis (2017–2024)
As of May 8, 2026, Ensysce Biosciences, Inc. (ENSC) generated trailing twelve-month (TTM) revenue of $4.5 million, reflecting significant decline in growth of -85.6% year-over-year. The most recent quarter (Q3 2025) recorded $493,104 in revenue, down 64.0% sequentially.
Looking at the longer-term picture, ENSC's 5-year compound annual growth rate (CAGR) stands at +24.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $5.2 million in 2024, representing a new all-time high.
Revenue diversification analysis shows ENSC's business is primarily driven by M P A R (0%).
When compared to Healthcare sector peers including COLL (+19.9% YoY), PCRX (+4.6% YoY), and AVDL (+79.9% YoY), ENSC has underperformed the peer group in terms of revenue growth. Compare ENSC vs COLL →
ENSC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ENSCCurrent | $4M | -85.6% | +24.2% | -129.2% | |
 COLL | $781M | +19.9% | +20.3% | 24.0% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 AVDL | $169M | +79.9% | +23.4% | -25.1% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% |
ENSC Historical Revenue Data (2017–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $5.2M | +133.5% | $-2,009,405 | -38.6% | $-6,730,000 | -129.2% |
| 2023 | $2.2M | -11.6% | $-5,357,000 | -240.1% | $-10,718,000 | -480.4% |
| 2022 | $2.5M | -28.5% | $-17,312,492 | -686.1% | $-24,222,095 | -959.9% |
| 2021 | $3.5M | -10.2% | $3.5M | 100.0% | $-19,870,431 | -562.7% |
| 2020 | $3.9M | +122.9% | $3.9M | 100.0% | $-1,613,287 | -41.0% |
| 2019 | $1.8M | - | $-1,638,340 | -92.9% | $-8,568,244 | -485.7% |
| 2018 | $0 | - | $-1,559,000 | - | $-959,000 | - |
| 2017 | $0 | - | $0 | - | $-147,000 | - |
See ENSC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ENSC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ENSC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonENSC — Frequently Asked Questions
Quick answers to the most common questions about buying ENSC stock.
Is ENSC's revenue growth accelerating or slowing?
ENSC revenue declined -85.6% year-over-year, contrasting with the 5-year CAGR of +24.2%. TTM revenue fell to $4M. This reverses the prior growth trend.
What is ENSC's long-term revenue growth rate?
Ensysce Biosciences, Inc.'s 5-year revenue CAGR of +24.2% reflects the variable expansion pattern. Current YoY growth of -85.6% is below this long-term average.
How is ENSC's revenue distributed by segment?
ENSC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2024 are available for download. Segment mix reveals concentration and diversification trends.